You are here: Industry Insights > BioLineRx

News List

Triple combination of therapies shows promise in pancreatic cancer trial europeanpharmaceuticalreview
December 18, 2020
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.
BioLineRx Initiates ARDS Trial americanpharmaceuticalreview
December 03, 2020
BioLineRx announced the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering from acute respiratory distress syndrome (ARDS) secondary to COVID-19 and ...
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory Distress Syndrome (ARDS) Secondary to COVID-19 and Other Respiratory Viral Infections prnewswire
November 19, 2020
BioLineRx Ltd., a clinical-stage biopharmaceutical Company focused on oncology, announced that the Company's lead drug candidate, the CXCR4-inhibitor Motixafortide, will be evaluated in an investigator-initiated clinical trial in patients suffering ...
BioLineRx Announces Positive Results from Trial of Motixafortide in Stem Cell Mobilization americanpharmaceuticalreview
November 11, 2020
BioLineRx announced positive results from a planned interim analysis of the ongoing GENESIS Phase 3 trial of motixafortide for stem cell mobilization (SCM) in multiple myeloma patients.
BioLineRx achieves enrolment target in phase 3 GENESIS Trial for planned interim analysis pharmaceutical-business-review
August 25, 2020
BioLineRx announced that a sufficient number of patients (~65% of the original planned sample size) have been enrolled in the ongoing GENESIS Phase 3 trial to allow for an interim efficacy analysis to take place in the second half of 2020.
BioLineRx Announces Notice of Allowance from USPTO for Motixafortide, Anti-PD-1 Combination americanpharmaceuticalreview
March 05, 2020
BioLineRx announced a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040).
BioLineRx Receives Orphan Drug Designation for Motixafortide for Pancreatic Cancer in Europe americanpharmaceuticalreview
January 19, 2020
BioLineRx announced the European Commission (EC) has granted Orphan Drug Designation to its lead oncology candidate, Motixafortide (BL-8040), for the treatment of pancreatic cancer, based on a positive opinion from the Committee for ...
BioLineRx Doses First Patient in Solid Tumor Immunotherapy Study americanpharmaceuticalreview
September 27, 2019
BioLineRx announced dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique ...
BioLineRx Successfully Completes Dose-Escalation Part for AGI-134 Study americanpharmaceuticalreview
September 04, 2019
BioLineRx has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect...
BioLineRx Announces FDA Approval of IND Application for AGI-134 americanpharmaceuticalreview
May 08, 2019
BioLineRx announced the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors.

Previous page 1 2 Next page